Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Vitamin D cuts the risk of pancreatic cancer

Consumption of Vitamin D tablets was found to cut the risk of pancreatic cancer nearly in half, according to a study led by researchers at Northwestern and Harvard universities.

12 Sep 2006

Morphotek granted two European technology patents

Morphotek has announced that the European Patent Office has given a "Decision of Grant" regarding the Company's US Patent 6,921,666 entitled "Methods for Generating Hypermutable Yeast" and US Patent 6,737,268 entitled "A Method for Generating Genetically Altered Antigens."

30 Aug 2006

Combining chemotherapy with radiation therapy after the surgical removal of cancer in the pancreas improves survival

Patients with pancreatic cancer, a historically difficult-to-treat cancer with poor survival rates, may benefit from treatments studied in an international, multi-center research trial.

26 Jul 2006

Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas

Most attempts to develop imaging agents that can better distinguish tumors from healthy tissue focus on finding molecules that are more abundant on malignant cells than on normal cells and using those as cellular targets.

10 Jul 2006

Reovirus could be used to treat many forms of advanced cancer

An experimental drug called Reolysin may give hope to patients suffering from advanced cancers, according to research presented at this year's meeting of the American Society of Clinical Oncology (ASCO).

8 Jun 2006

Addition of gemcitabine to standard postoperative treatment increased pancreatic cancer patients' survival by 50 percent

Adding the cancer-fighting drug gemcitabine to standard therapy after surgery significantly improves survival for patients with the most common form of pancreatic cancer, according to a new multicenter study led by a University of Maryland radiation oncologist.

6 Jun 2006

New data show Enzastaurin's activity across multiple cancer cell lines

Eli Lilly and Company's enzastaurin, an investigational, multi-targeted therapy that is currently the focus of two global Phase III clinical trials, one for the treatment of glioblastoma and one in non-Hodgkin's lymphoma

5 Jun 2006

Blood pressure drugs associated with reduced risk of cancers

Thousands of individuals currently taking angiotension converting enzyme (ACE) inhibitors, a type of medication commonly used to lower blood pressure, may be doing more than treating their hypertension.

31 May 2006

Ingredient in red chili pepper has cancer-fighting properties

The study found that capsaicin, the "hot" ingredient in red chili pepper, caused pancreatic cancer cells to die through a process called apoptosis.

13 Apr 2006

Lilly launches phase III trial of Enzastaurin

One of the deadliest and rarest forms of cancer is the focus of a Phase III study initiated by Eli Lilly and Company today.

9 Mar 2006

Avastin trial for pancreatic tumors

"Our findings from the previous study suggest that the combination of chemotherapy and radiation is a safe and effective treatment method to reduce the local extent of pancreatic tumors," said Dr. Talamonti.

23 Feb 2006

Cathepsin inhibitors as cancer therapies

In the March 1 issue, Drs. Johanna Joyce (MSKCC), Douglas Hanahan (UCSF) and colleagues lend new insight into how broad-spectrum cysteine cathepsin inhibitors combat pancreatic cancer, and provide new data to help refine the design of more precisely targeted anti-cathepsin therapies.

17 Feb 2006

Targeted cancer therapies: Another step forward

While it is clear that the treatment of cancer has already begun to undergo a paradigm shift with the inclusion of innovative targeted therapies into current regimens, it would be wrong to assume these products will entirely replace traditional chemotherapy as the standard treatment for cancer sufferers.

22 Dec 2005

Targeted cancer therapies: Another step forward

22 Dec 2005

Liver plays crucial role in iron metabolism

A new study in the December Cell Metabolism reveals an unexpected connection between a tumor suppressor gene in the liver and the normally careful control over the amount of iron absorbed from the diet.

7 Dec 2005

Pancreatic cancer and ecoendoscopy

Cancer of the pancreas is the number five in the list of deaths due to cancers in Spain and the third causing deaths due to digestive tumour.

28 Nov 2005

Potential new treatment for pancreatic cancer

Johns Hopkins Kimmel Cancer Center researchers are encouraged by early results of a treatment vaccine for pancreatic cancer, a disease with few options and low odds for long-term survival.

28 Nov 2005

Pancreatic cancer vaccine extends survival

In a long awaited positive development, an experimental pancreatic cancer vaccine seems to be extending survival rates higher.

16 Nov 2005

Gene therapy potential of the protein vasostatin for treatment of pancreatic cancer

A gene responsible for the production of a protein called vasostatin may prove a promising new way of treating pancreatic cancer, suggests research published ahead of print in Gut.

15 Nov 2005

Capecitabine and Gemcitabine help battle pancreatic cancer

The prognosis of pancreatic cancer is poor but new therapies such as gemcitabine have contributed to improving the outcome for patients. Data presented at the 13th European Conference (ECCO) revealed that using the combination of gemcitabine and capecitabine increased overall survival in some patients.

3 Nov 2005